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Background: Human cytomegalovirus (CMV) is an ubiquitous pathogen capable of modulating the host immune
system. Immune dysfunction is common during CMV infection and includes autoimmune phenomena. Here we
focus on a case of primary CMV infection associated with encephalopathy in a patient with a rudimentary spleen.
We discuss diagnostic challenges and immunological aspects as well as the hypothesis that CMV may break
tolerance and induce potentially encephalitogenic autoantibodies.
Case presentation: A 33-year-old woman was admitted with features of encephalitis, rapidly progressing into a
catatonic state. The patient tested negative for presence of herpes simplex virus DNA in cerebrospinal fluid (CSF),
and had elevated liver enzymes and hepatomegaly at computed tomography scan (CT) examination. CT scan and
magnetic resonance imaging (MRI) showed only a rudimentary spleen. Initially, serum was negative for anti-CMV
IgM, but borderline for anti-CMV IgG by enzyme-linked immunosorbent assay. However, a more sensitive assay
resulted in a positive specific IgM Western blot profile and low IgG avidity, suggesting primary CMV infection.
Further, CMV DNA was retrospectively detected in a CSF sample collected at admission. We also detected
antineuronal autoantibodies, which stained GAD-positive neurons in the hippocampus. The patient was treated by
a combination of prednisone, intravenous immunoglobulins (IVIg) and antivirals, which resulted in a dramatic
amelioration of the patient’s neurological status. One year after admission the patient exhibited a nearly complete
recovery with mild deficits in attention and memory.
Conclusions: A possible reason for the critical course of CMV infection could be the lack of a functional spleen in
this patient, a condition previously associated with severe CMV infection. Prompt treatment with antiviral drugs,
steroids and IVIg was most likely important for the positive outcome in this case and should be considered for
similar cases of severe primary CMV infection associated with immunopathological phenomena.
Keywords: Human cytomegalovirus, Encephalitis, Antineuronal autoantibodiesBackground
Human cytomegalovirus (CMV) is an ubiquitous patho-
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with autoimmune diseases, the virus can replicate at
sites of inflammation [4], highlighting CMV’s potential
role in inducing or maintaining immunopathology. Here
we focus on a case of primary CMV infection associated
with encephalopathy in a patient with a rudimentary
spleen. We discuss diagnostic challenges and immuno-
logical aspects as well as the hypothesis that CMV may
break tolerance and induce potentially encephalitogenic
autoantibodies. Finally, the clinical utility of antivirals
combined with intravenous immunoglobulins (IVIg) and
prednisone in the treatment of severe CMV infections is
highlighted.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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A 33-year-old woman presented to the emergency room
at Karolinska University Hospital, Huddinge, Sweden,
with a history of confusion, fatigue, impaired memory
and headache. Symptom onset and duration was unclear;
the patient had experienced an upper respiratory tract
infection 10 days earlier. The medical history was unre-
markable, except an episode of acute idiopathic throm-
bocytopenic purpura (ITP) 15 years earlier. After
admission, the confusion progressed and the patient
experienced mild speech difficulties in terms of response
latency and difficulty in finding words. She also had
memory impairment and motor agitation. The patient
was swaying whilst performing the Romberg test and
had tremors. Altered mental status with confusion and
impaired memory aroused suspicion of limbic encephal-
itis. Initial blood tests including leukocyte count (9.5 x
109/L) and C-reactive protein (Figure 1A) were normal.
Cerebrospinal fluid (CSF) had a high concentration of al-
bumin, as a sign of barrier injury, and normal cell count.
The patient was admitted to the Neurology Department
of the same hospital and empirically treated with acyclo-
vir under suspicion of herpes simplex type I (HSV-I) en-
cephalitis. As CSF tested repeatedly negative for HSV-1
DNA by a high sensitive real-time PCR [5], acyclovir
was discontinued.
On Day 9 after admission, a short loss of conscious-
ness was reported, and on Day 10 the patient was found
unconscious, with tonic extensions/spasms of the ex-
tremities, involuntary loss of urine and tongue bites.
Despite administration of Diazepam and Fosphenytoin,
the patient remained unconscious and was transferred to
the Intensive Care Unit (ICU) (Figure 1B). She thereafter
entered a catatonic condition. Continuous electroen-
cephalography (EEG) monitoring showed frontal bilat-
eral sparse hints of sharp waves/epileptic activity but no
certain seizure activity. After this episode, the patient
had several seizures in form of tonic extensions/spasms
of the extremities with autonomic influence and she was
treated at the ICU at 4 more occasions. Repeated EEG
examinations did not show any epileptic or seizure activ-
ity even when the patient experienced tonic extensions/
spasms.
At Week 3, the patient presented myoclonic jerks in
all four extremities with irregular pattern, which were
triggered by auditory and sensory stimuli. Occasionally,
the patient also exhibited ophistotonus. EEG examina-
tions was performed while the patient exhibited these
jerks, but no signs of epileptic changes or seizure activity
were found, suggesting cortical myoclonus and brain-
stem evoked decerebration seizures.
Computed tomography (CT) and magnetic resonance
imaging (MRI) head scans did not show any signs of
cerebrovascular insult, or malignancy. Nevertheless,accumulation of contrast signal was detected by MRI in
pons, brainstem, thalamus and in the cerebellar lepto-
meninges (Figure 1C), which was judged as a non-
specific sign of inflammation.
The patient had elevated liver enzymes (Figure 1A and
data not shown) and hepatomegaly at CT examination,
which led to the suspicion of autoimmune liver disease.
In support of this, the patient exhibited hypergammaglo-
bulinemia and anti-nuclear, anti-smooth muscle cell and
anti-SS-A52 autoantibodies. Several other autoantibodies
were also detected, including anti-MitoM2, M2-3E, gp120,
Sp100, PML and anti-mitochondrial autoantibodies in-
dicating primary biliary cirrhosis as well as anti-Ro52,
anti-Ro60, SS-B and anti-dsDNA antibodies as in Sjög-
ren’s syndrome or systemic lupus erythematosus. How-
ever, a biopsy of the lip salivary gland was negative for
histological hallmarks of Sjögren’s syndrome and no
other systemic autoimmune disease could be confirmed.
CT scan and MRI showed only a rudimentary spleen.
Notably, the patient’s former medical history of ITP did
not involve splenectomy.
At Week 23 after disease onset the total T-cell count
was normal (5x109 cells/L), but low levels of CD4+ T
cells and increased levels of CD8+ T cells were observed
(38% and 87% of total T cells, respectively). The B-cell
count was lower than normal and T- and B-cell prolif-
eration upon mitogen stimulation was impaired (data
not shown).
At admission, serum and CSF samples tested negative
for varicella–zoster virus, borrelia, Treponema pallidum,
and toxoplasma and revealed past contact for Epstein-
Barr virus, adenovirus, and measles. Of note, a serum
sample tested negative for anti-CMV IgM, but border-
line for anti-CMV IgG by enzyme-linked immunosorb-
ent assay. Because of the unclear result for specific IgG,
a blood sample was analysed at Week 5 and tested posi-
tive for CMV DNA, indicating active CMV replication
(Figure 1B). A CSF sample collected at admission was
retrospectively analysed and CMV DNA was detected by
PCR. Two serum samples, obtained from the patient at
admission and ten days later, retrospectively showed a
positive specific IgM profile by immunoblot analysis
(method described in [6]) and low IgG avidity, suggestive
of primary CMV infection.
Empirical treatment with intravenous high-dose corti-
sone was initiated during Week 3 (Figure 1B), followed
by oral prednisone and intravenous immunoglobulins
(IVIg) at Week 4. When the diagnosis of active CMV in-
fection was confirmed, intravenous ganciclovir treatment
was initiated in combination with prednisone; adminis-
tration of antivirals and steroids was continued daily in a
course of 5 months, while IVIg were administered in an
intermittent way in nine doses (Figure 1B and data not
shown). This therapy resulted in a dramatic amelioration
Figure 1 (A) Laboratory values. Normal ranges: C-reactive protein (CRP), <5 mg/L; alanine aminotransferase (ALAT), <0.75 microkat/L. (B)
Clinical course and treatment. ICU; admission to intensive care unit. Prednisone was administered at 80 mg/day (starting at Week 3) and later
adjusted to 60 mg/day in a lowering dose until complete drug withdrawal. Ganciclovir was started at Week 6 at 5 mg/kg per day. Antivirals were
administered consecutively for 5 months, while IVIg (0.4 g/kg/day on 5 days) was administered on a three week-basis. (C) and (D) Imaging
findings. Twenty days after disease onset, T2-weighted MRI scans showed increased signal in the pons (arrowheads), mesencephalon, globus
pallidus, and external capsula while six months later (D) complete regression of the signal enhancement (arrowheads) and an intact blood–brain
barrier were observed.
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nations of the brain showed regression of pathological
signs (Figure 1). Liver enzymes normalized (Figure 1A).
CMV DNA load decreased and then tested negative
(Figure 1B). After four months, the patient wasdischarged to a rehabilitation ward. She remained on
antivirals for a total of five months while prednisone was
diminished on a scalar basis until complete discontinu-
ation after 11 months. One year after admission the pa-
tient exhibited a nearly complete cognitive recovery with
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examination the only sequelae were oscillating eye
movement at abduction, minor sporadic myoclonus and
slightly impaired balance. The patient is now living by
herself and attending college.
Immunological findings
At Week 10, IFN-γ production by CD4+ and CD8+ T
cells was low in response to CMV antigens. In addition,
T-cell responses to S. aureus Enterotoxin B (SEB) were
also low, indicating a general impairment of cellular im-
munity (Figure 2A and data not shown). CMV-specific
CD4+ and CD8+ T-cell response, particularly to the im-
munodominant antigen pp65, was impaired up to Week
62 (Figure 2A and data not shown, method described in
[7]). Conversely, high levels of IFN-γ were observed in
plasma at Week 2 (499 pg/mL) and were maintained at
Week 21 (154 pg/mL; reference values obtained from 13
healthy donors; 10 ± 28 pg/mL, mean ± standard devi-
ation (data not shown).
At Week 12 low levels of BDCA-1+ (CD1c) and
BDCA-3+ (CD141) myeloid dendritic cells (DCs) and
BDCA-2+ (CD303) plasmacytoid DC were detected and
remained impaired up to Week 24 (Figure 2C and D).
Neuroimmunological findings
Since the patient presented with clinical signs of limbic
encephalitis (cognitive impairment, seizures and patho-
logic MRI-scan), the presence of autoantibodies against
antigens known to be involved in triggering this patho-
logical condition was investigated [8]. Serum and CSF
samples were negative for anti-Hu, anti-Ma, anti-voltage
gated potassium channel, anti-collapsin response medi-
ator protein-5 as well as for autoantibodies against the
N-methyl-D-aspartate (NMDA) receptor. Further, we
screened for the presence of neuronal autoantibodies, by
applying patient serum to sections of murine brains as
described [9]. A strong staining in neurons of cortex
and hippocampus but not in glial cells was observed
(Figure 2E and F). To assess the specificity of this finding,
sera from 3 healthy CMV IgG-negative and 6 CMV IgG-
positive controls were investigated; very weak or absent
staining was observed (Figure 2G and data not shown).
Interestingly, many – but not all – neurons in hippocam-
pus that were stained by the patient serum were also
immunoreactive for glutamic acid decarboxylase (GAD)
(Figure 2H, inset).
Discussion
Here, we describe a case of primary CMV infection asso-
ciated with encephalitis and autoimmune phenomena in
a young woman. This case was unusual for several rea-
sons: i) CMV infections involving the central nervous
system are uncommon in previously healthy individuals[10]; ii) an impaired CMV-specific T-cell response was
observed for several months after infection; iii) the pa-
tient developed antineuronal autoantibodies directed
against neurons in the hippocampus.
First, the patient exhibited a rudimentary spleen, which
could have contributed to the lack of development of a
proper anti-CMV immune response leading to severe in-
fection. In fact, the spleen is crucial for development of
IgM memory B-cells, which are important for immunity
against viruses, including CMV [11] and splenectomised
patients have been described to suffer from more severe
CMV infections than eusplenic patients [12].
The poor IgM development against CMV in patients
with a dysfunctional or absent spleen may complicate
diagnostic procedures [11]. In our case, IgM against
CMV tested negative during the active phase of infection
by employing a commercial immunoenzymatic assay,
which delayed the time to diagnosis. The diagnosis was
eventually established through detection of circulating
CMV DNA. Further, by the use of a more sensitive IgM
Western blot method, IgM antibodies could be detected,
which confirmed the diagnosis of active CMV infection.
The immunological status of the patient at disease
onset showed low B-cell count as well as deficient
lymphocyte proliferative response to mitogens. As a fur-
ther sign of impaired immunity, circulating DC count
was low; this is a common finding during primary symp-
tomatic CMV infection in adults, as we recently
reported [13]. Cytotoxic T lymphocytes (CTL) appear to
play an important role in the control of CMV infection,
70-90% of all CTL being specific for the viral antigen
pp65 [14]. Importantly, CD4+ and CD8+ T-cell responses
to pp65 remained impaired up to Week 62 in our pa-
tient, while high plasma levels of IFN-γ suggest activa-
tion of innate mechanisms to compensate for the lack
of CMV-specific responses. We hypothesize that un-
controlled viral replication in a subject with previously
hidden immune-defects may have caused the virus to
reach the central nervous system, thus triggering viral
encephalitis. However, we cannot exclude that the virus
per se may have contributed to impeding the host re-
sponse. In fact, it is known that CMV inhibits antigen
presenting cell function leading to impaired T cell re-
sponses (as reviewed in [15]) and alters mitogen-induced
lymphocyte proliferation [16,17].
A third unusual feature of this case is that we detected
autoantibodies with strong specificity to neurons;
primary CMV infection may have contributed to the
break of self-tolerance and to a broad polyclonal acti-
vation of B-cell clones with the final result of several
autoantibodies, including those binding to neurons.
Many neuronal antibodies stained cells that were GAD-
positive, suggesting that the GABAergic system might be
involved in the development of the observed
Figure 2 (A,B) Percentages of CD4+ T cells producing IFN-γ in response to CMV immediate early (IE) antigen-1 and pp65 in the patient
(A) and 7 CMV-seropositive donors (B). S. aureus enterotoxin B (SEB) served as positive control. PBMC; peripheral blood mononuclear cells.
(C,D) Enumeration of DC subsets in the patient (C) and 13 donors (D). BDCA; blood dendritic cell antigen. (E-H) Neuroimmunological
findings. (E,G) Hippocampal neurons (granular [Gr] and pyramidal [Pyr] cell layers) after immunostaining with patient serum (green, 1:25,000) (E)
or serum from control (1:5,000) (G). (F, H) Double-labeling with patient serum (green) and GAD (red). Arrows and inset indicate double-labelled
cells. Arrowhead; GAD-positive serum-negative cell.
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been linked to cerebellar ataxia and seizures [18]. How-
ever, since not all serum IgG-positive cells expressed
GAD, other autoantigen(s) may be involved in the actual
case.
A key observation that links active CMV infection and
viral-induced immunopathology to the overall clinical
presentation is the fact that the onset of a combinedtreatment including antivirals, immunomodulatory IVIg
and prednisone coincided with a rapid improvement of
the patient’s clinical status (Figure 1B). Therapeutical ef-
fect of single drugs could not be discerned, as ganciclo-
vir and immunomodulatory drugs were administered
simultaneously. It is known that antivirals are effective in
the management of direct effects caused by CMV replica-
tion in immunocompromised patients [4], while optimal
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remains obscure; it is possible that IVIg and prednisone
contributed to the positive outcome in this case.
Conclusion
The patient described here had a primary CMV infec-
tion, which was associated with clinical and radiological
signs of encephalitis. A possible reason for the critical
course of CMV infection could be the lack of a func-
tional spleen in this patient, a condition previously as-
sociated with severe CMV infection. Supporting this
possibility, we observed poorly responding T cells to
CMV antigens which lasted several months after the
infection’s onset. CMV encephalitis in immunocompe-
tent individuals has been associated with mild signs of
inflammation of the CNS, including absent to moderate
pleocytosis [19-21]. Our patient exhibited normal cell
count and the presence of CMV DNA in the CSF at dis-
ease’s onset. Our main hypothesis is that primary CMV
infection was the first insult and had a fulminant course
because of the patient’s immune status (asplenic). Toler-
ance was broken and autoimmunity ensued. Infection of
the CNS and general inflammation may have injured the
blood brain barrier, thus allowing pathogenetic serum
antibodies to enter the brain and cause neuronal dam-
age. In support to our hypothesis, the need of an in-
flammatory trigger to allow serum antibodies to bind
neurons in the brain has been demonstrated in a murine
model of lupus [22]. Because autoantibodies binding to
GAD-positive neurons were detected in this patient, we
propose that the emerging concept of autoantibody-
mediated encephalitis should be included in the differen-
tial diagnostic algorithm for patients presenting with
signs of viral encephalitis as the two conditions may
overlap. Prompt treatment with antiviral drugs, steroids
and IVIg was most likely important for the positive out-
come in this case and should be considered for similar
cases of severe primary CMV infection associated with
immunopathological phenomena.
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